Ashley Gallagher, Editor

Although sun-protective measures have been increasing, the incidence of skin cancer has also increased, suggesting better targeted interventions and patient education are needed.

Australia, Québec, and Sweden have defined processes for reimbursements by health technology assessments, but the United States has a low reliance rate.

The GLP-1 market is expected to exceed $100 billion by 2023, according to J.P. Morgan Research, with total users in the United States projected to reach 30 million.

Aflibercept-jbvf (Yesafili; Biocon Biologics) and aflibercept-yszy (Opuviz; Biogen, Samsung Bioepis) are the first interchangeable biosimilars to aflibercept (Eylea; Regeneron).

Belimumab (Benlysta; GSK) is a B-lymphocyte stimulator-specific inhibiting monoclonal antibody.

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

The prevalence of transmission was higher for those who had contact with children aged less than 5 years and aged 5 to 9 years compared with children aged older than 10.

Corticophobia is defined as a phobia of topical corticosteroids due to negative feelings or beliefs, which can come from misinformation about the long-term effects.

According to the results, approximately 82% of adults said they have heard at least a little about GLP-1 medications and 32% said they have heard a lot.

The American Association of Colleges of Pharmacy led a pharmacy education seminar in Cuba discussing cultural differences and approaches to medication and care.

The study’s co-primary endpoint of overall survival was not formally tested due to DFS not being reached.

In diabetic rats, investigators found a decrease in urine biomarkers and expression of proteins that play a part in renin-angiotensin system (RAS).

Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to control bleeding.

The data were previously presented at the Multilateral Initiative on Malaria 8th Pan-African Malaria Conference and have been submitted for regulatory review.

A provisional determination is also provided for the 40 mg/0.4 mL strength due to remaining interchangeability designation for another biosimilar to Humira.

Investigators noted that the conditional overall survival also had clinically meaningful improvements compared with sorafenib for advanced renal cell carcinoma.

The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.

This is the first FDA advisory committee meeting that will review a potential new posttraumatic stress disorder treatment in 25 years.

The vaccine protected against serotypes 19A and 19F, but statistical significance was not reached for serotype 3.

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.

Retail sales were associated with lower e-cigarette use, although recreational legalization also increased the frequency of cannabis use among adolescents.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

Naloxone hydrochloride (Amneal Pharmaceuticals Inc) is the generic equivalent to OTC Narcan (Emergent).

Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

With migraine as a leading disability for those under the age of 50, treatment options for migraine should be personalized to the patient and their needs.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.